Zydus Lifesciences Limited (BOM:532321)

Market Cap	981.03B
Revenue (ttm)	232.42B
Net Income (ttm)	45.26B
Shares Out	n/a
EPS (ttm)	44.97
PE Ratio	21.68
Forward PE	21.63
Dividend	11.00 (1.14%)
Ex-Dividend Date	Jul 25, 2025

Volume	29,767
Average Volume	50,401
Open	968.60
Previous Close	968.50
Day's Range	962.00 - 975.80
52-Week Range	797.05 - 1,323.90
Beta	n/a
RSI	52.35
Earnings Date	Aug 8, 2025

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 27,917
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.